Research ArticleBasic Science Investigations

Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab

Constantijn H.J. Muselaers, Alexander B. Stillebroer, Mark Rijpkema, Gerben M. Franssen, Egbert Oosterwijk, Peter F.A. Mulders, Wim J.G. Oyen and Otto C. Boerman
Journal of Nuclear Medicine June 2014, 55 (6) 1035-1040; DOI: https://doi.org/10.2967/jnumed.114.137356

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    (A) Micro-SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 1 and 3 d after injection of 125I-girentuximab-IRDye800CW. In addition to tumor uptake, minimal uptake in heart and thyroid was observed. (B) Optical images of same mouse at 1 and 3 d after injection (same image settings were used for days 1 and 3). Some reflectance-induced image artifacts on backs of mice were observed. (C) Micro-SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 1 and 3 d after injection of 125I-girentuximab. (D) Biodistribution of 125I-girentuximab-IRDye800CW and 125I-girentuximab in mice with subcutaneous SK-RC-52 tumor at 3 d after injection. Values are expressed as mean ± SD. T/B ratio = tumor-to-blood ratio.

  • FIGURE 2.
    FIGURE 2.

    (A) Optical images of mouse bearing CAIX-positive SK-RC-52 tumor on left flank and CAIX-negative SK-RC-59 tumor on right flank (arrows) at 1 and 3 d after injection of 125I-girentuximab-IRDye800CW (same image settings were used for days 1 and 3). Some reflectance-induced image artifacts on backs of mice were observed. (B) Biodistribution at 3 d after injection of 125I-girentuximab-IRDye800CW or 125I-MOPC21-IRDye800CW in mice with subcutaneous SK-RC-52 tumor and subcutaneous SK-RC-59 tumor. Values are expressed as mean ± SD.

  • FIGURE 3.
    FIGURE 3.

    Ex vivo biodistribution of 125I-girentuximab-IRDye800CW and excess unlabeled girentuximab. T/B ratio = tumor-to-blood ratio.

  • FIGURE 4.
    FIGURE 4.

    (Left) Preoperative fluorescence image of mouse with subcutaneous growing ccRCC tumor lesion at 3 d after injection with 125I-girentuximab-IRDye800CW. (Middle) Tumor lesion was subsequently removed by fluorescence image–guided surgery. (Right) After resection, no residual tumor was detected by fluorescence imaging or macroscopically.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords